MIA-602

News alerts, weekly reports and conference planners

Company:

University of Miami

Drug class:

GHRH antagonist

‹

›

9ms

Growth Hormone-Releasing Hormone (GHRH) Antagonist Peptides Combined with PI3K Isoform Inhibitors Enhance Cell Death in Prostate Cancer. (PubMed, Cancers (Basel))

The ability of the MIA-602/690 + PI3K inhibitor combination to alter multiple signaling pathways may weaken the activation of adaptive mechanisms resulting from each drug and improve efficacy.

9 months ago

Journal

PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • CCNA2 (Cyclin A2) • E2F1 (E2F transcription factor 1)

PIK3CA mutation • PTEN mutation

MIA-602

10ms

Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells. (PubMed, Int J Mol Sci)

Finally, both MIA-602 and MIA-690 enhanced radiosensitivity in primary human NSCLC cells. These findings highlight the potential of GHRH antagonists as radiosensitizers in NSCLC treatment.

10 months ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • IGF1 (Insulin-like growth factor 1) • CASP3 (Caspase 3)

MIA-602

over2years

The Application of GHRH Antagonist as a Treatment for Resistant APL. (PubMed, Cancers (Basel))

Additionally, combination therapy with both doxorubicin (DOX) and MIA-602 showed a marked synergistic effect in reducing the proliferation of the K-562 AML cell line. These findings suggest that MIA-602 could be utilized to address resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) therapies, as well as in augmenting anthracycline-based regimens.

over 2 years ago

Journal

doxorubicin hydrochloride • arsenic trioxide • MIA-602